Editorial comment.

J Urol

Published: January 2010

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.08.198DOI Listing

Publication Analysis

Top Keywords

editorial comment
4
editorial
1

Similar Publications

Carbapenem-resistant (CRAB) remains a major threat, with high mortality and limited effective treatments. Sulbactam-durlobactam has emerged as a promising therapy against CRAB. Sulbactam-durlobactam was combined with imipenem-cilastatin in a clinical trial that led to its United States Food and Drug Administration approval.

View Article and Find Full Text PDF

Editorial Comment.

J Urol

March 2025

Department of Urology, Eastern Health, Box Hill,Victoria, Australia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!